

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Brilliant Violet 785(TM) anti-mouse CD103

RRID:AB_2800588

Type: Antibody

Proper Citation

BioLegend Cat# 121439, RRID:AB_2800588

Antibody Information

URL: http://antibodyregistry.org/AB_2800588

Proper Citation: BioLegend Cat# 121439, RRID:AB_2800588

Target Antigen: CD103

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse CD103

Description: This monoclonal targets CD103

Target Organism: mouse

Clone ID: Clone 2E7

Antibody ID: AB_2800588

Vendor: BioLegend

Catalog Number: 121439

Record Creation Time: 20250820T061515+0000

Record Last Update: 20250820T233805+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD103.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD103.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. *Cell reports. Medicine*, 6(9), 102307.

Vidal SJ, et al. (2025) Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines. *Cell*.

Lecointre M, et al. (2025) HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine. *Cancer discovery*, 15(7), 1458.

Wang M, et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. *Cancer discovery*, 15(9), 1883.

Wang L, et al. (2025) Mucosal boosting increases protective efficacy of an influenza vaccine in mice. *iScience*, 28(6), 112721.

Castaño D, et al. (2025) Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. *Cell*, 188(26), 7461.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. *Cell reports*, 43(5), 114141.

Dean JW, et al. (2023) The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8+ T cell differentiation and function. *Cell reports*, 42(1), 111963.

Gurram RK, et al. (2023) Crosstalk between ILC2s and Th2 cells varies among mouse models. *Cell reports*, 42(2), 112073.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. *Immunity*, 56(1), 207.

Zhou R, et al. (2022) Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. *EBioMedicine*, 75, 103762.